Artal Group S.A. Arrowhead Pharmaceuticals, Inc. Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $3.34 Million - $4.31 Million	152,721 Added 5.03%	3,189,389 $82.9 Million
Q1 2024 May 13, 2024	BUY	$27.21 - $39.48 $54.6 Million - $79.3 Million	2,008,413 Added 195.32%	3,036,668 $86.8 Million
Q4 2023 Feb 09, 2024	BUY	$21.2 - $31.03 $21.7 Million - $31.7 Million	1,022,815 Added 18801.75%	1,028,255 $31.5 Million
Q2 2023 Aug 11, 2023	SELL	$25.16 - $41.38 $521,642 - $857,931	-20,733 Reduced 79.22%	5,440 $194,000
Q1 2023 May 12, 2023	BUY	$23.68 - $38.51 $619,776 - $1.01 Million	26,173 New	26,173 $665,000
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $15.7 Million - $26 Million	-600,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$20.56 - $63.12 $12.3 Million - $37.9 Million	600,000 New	600,000 $17.3 Million

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.